Torrent Pharmaceuticals Ltd's Q3FY25 Quarter Results
- 25 Jan 2025
Result Summary
- Torrent Pharmaceuticals Ltd reported a 1.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 5.3%.
- Its expenses for the quarter were down by 2.8% QoQ and 0.2% YoY.
- The net profit increased 11.0% QoQ and increased 13.5% YoY.
- The earnings per share (EPS) of Torrent Pharmaceuticals Ltd stood at 14.9 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 2842.00 | 2873.00 | 2699.00 | -1.1% | 5.3% |
Total Expenses | 2151.00 | 2212.00 | 2156.00 | -2.8% | -0.2% |
Profit Before Tax | 691.00 | 661.00 | 631.00 | 4.5% | 9.5% |
Tax | 188.00 | 208.00 | 188.00 | -9.6% | 0.0% |
Profit After Tax | 503.00 | 453.00 | 443.00 | 11.0% | 13.5% |
Earnings Per Share | 14.90 | 13.40 | 13.10 | 11.2% | 13.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Torrent Pharmaceuticals Ltd is a leading pharmaceutical company engaged in the development, manufacturing, and commercialization of a wide range of pharmaceutical products. The company operates in the healthcare sector, focusing on a diverse portfolio that includes therapeutic areas such as cardiovascular, central nervous system, gastro-intestinal, and anti-infective segments. Torrent Pharmaceuticals has a strong presence in both the domestic and international markets, with a significant emphasis on research and development. The company continuously strives to enhance its product offerings and expand its market reach. As of the latest available data, there were no specific major developments highlighted for the period under review.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Torrent Pharmaceuticals Ltd reported a total income of ₹2,842 crores, compared to ₹2,873 crores in the previous quarter (Q2FY25), reflecting a quarter-over-quarter (QoQ) decrease of 1.1%. On a year-over-year (YoY) basis, the total income showed an increase of 5.3% from ₹2,699 crores in Q3FY24. The company’s revenue performance indicates a solid annual growth despite a slight decline in the recent quarter. This performance in total income is a key aspect of the company's overall financial health, with the YoY growth suggesting resilience in revenue generation over the past year.
Profitability
Torrent Pharmaceuticals Ltd's Profit Before Tax (PBT) for Q3FY25 was ₹691 crores, an increase from ₹661 crores in Q2FY25, marking a QoQ growth of 4.5%. Compared to the same quarter in the previous fiscal year, the PBT rose by 9.5% from ₹631 crores in Q3FY24. The company's Profit After Tax (PAT) for Q3FY25 stood at ₹503 crores, up from ₹453 crores in Q2FY25, translating to an 11.0% QoQ increase. The PAT also experienced a YoY growth of 13.5% from ₹443 crores in Q3FY24. Earnings Per Share (EPS) followed a similar trend, with an 11.2% QoQ increase to ₹14.90 in Q3FY25, and a 13.7% YoY rise from ₹13.10 in Q3FY24. These metrics indicate the company's ability to maintain and enhance profitability.
Operating Metrics
The total expenses for Q3FY25 were ₹2,151 crores, which represented a decrease of 2.8% QoQ from ₹2,212 crores in Q2FY25, and a slight decrease of 0.2% YoY from ₹2,156 crores in Q3FY24. The reduction in expenses quarter-over-quarter indicates efficient cost management during this period. The tax expense for Q3FY25 was ₹188 crores, down from ₹208 crores in Q2FY25, showing a QoQ decrease of 9.6%, while remaining consistent with the previous year’s Q3FY24 figure of ₹188 crores. The consistent tax values and reduced expenses contribute to the company’s financial stability, impacting the overall profitability positively. These operational metrics are crucial for understanding the company's cost structure and tax efficiency over the reviewed periods.
